Constellium (CSTM) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
18 Feb, 2026Executive summary
Achieved record Q4 and strong full-year 2025 results, surpassing expectations despite macroeconomic and end-market uncertainty.
Demonstrated robust cost control, operational excellence, and capital discipline, positioning well for 2026 opportunities.
Launched Vision 2028 program to drive productivity, automation, operational efficiencies, and cost reductions.
Returned $115 million to shareholders via repurchase of 8.9 million shares and reduced leverage to 2.5x.
Benefited from improved operational performance at Muscle Shoals and post-flood recovery in Valais.
Financial highlights
Q4 2025: Shipments 365k tons (+11% YoY), revenue $2.2B (+28% YoY), net income $113M, Adjusted EBITDA $280M (includes $67M positive metal price lag), free cash flow $110M.
FY 2025: Shipments 1.5M tons (+4% YoY), revenue $8.4B (+15% YoY), net income $275M, Adjusted EBITDA $846M (includes $126M positive metal price lag), free cash flow $178M.
2025 adjusted EBITDA (excluding metal price lag) was the second-best year ever.
Returned $115 million to shareholders via repurchase of 8.9 million shares.
Free Cash Flow of $178 million for 2025, a significant improvement from $(100) million in 2024.
Outlook and guidance
2026 Adjusted EBITDA (excluding metal price lag) targeted at $780–$820 million; Free Cash Flow expected to exceed $200 million.
2028 targets reiterated: $900 million Adjusted EBITDA and $300 million Free Cash Flow.
Guidance assumes stable macro environment and continuation of recent demand trends.
Leverage targeted at 1.5x–2.5x for 2026.
Capex for 2026 expected at ~$315M, cash interest ~$125M, cash taxes ~$70M.
Latest events from Constellium
- Record Q2 and H1 results, raised 2026 guidance, and strong segment-driven profit growth.CSTM
Q2 2026 - Record Adjusted EBITDA and net income, with raised 2026 outlook and strong liquidity.CSTM
Q1 2026 - Director appointments, executive pay, and share repurchase authorizations recommended for approval.CSTM
Proxy filing - Shareholders will vote on director appointments, executive pay, financials, and share repurchases.CSTM
Proxy filing - Shareholders to vote on director appointments, executive pay, and share repurchase plans after a strong 2025.CSTM
Proxy filing - Q3 2024 results were hit by lower volumes, flood losses, and weak demand across key markets.CSTM
Q3 2024 - Q2 2024: Net income rose, cash flow strong, Swiss flooding paused guidance, 2025 target reaffirmed.CSTM
Q2 2024 - Revenue up 5% and net income up 73% in Q1 2025, with guidance reaffirmed.CSTM
Q1 2025 - 2024 saw lower results from disruptions, but 2025–2028 targets reflect recovery and growth.CSTM
Q4 2024